Adlai Nortye receives rights to solid tumor candidate E7046 from Eisai

Eisai Co. Ltd. (Tokyo:4523) granted Adlai Nortye Co. Ltd. (NEEQ:870946) exclusive, worldwide rights outside of parts of Asia to develop and commercialize solid tumor candidate E7046. Specifically, the deal excludes Japan, Korea, Taiwan, Thailand, India, Philippines, Indonesia, Singapore, Malaysia, Vietnam, Myanmar, Laos and Cambodia. E7046 is a prostaglandin E2 (PGE2) receptor EP4 subtype (prostanoid EP4 receptor; PTGER4) antagonist. Adlai Nortye expects results from a Phase Ib trial in 1Q19...